Risk factors for coronary artery disease in familial hypercholesterolemia

Abstract

Individuals with familial hypercholesterolemia are at markedly increased risk of coronary artery disease (CAD). Accurate risk assessment and appropriate management in this population are therefore crucial. In this review, we summarize findings from several studies that have investigated predictors of CAD in familial hypercholesterolemia (FH). The main categories of predictors include demographic variables and comorbidities, lipid-related parameters, physical findings such as xanthomas, genetic characteristics, and imaging markers of atherosclerosis. We also highlight risk prediction models developed from these previously published findings.

Keywords

Genetic diseases / inborn / hyperlipoproteinemias / atherosclerosis

References

[1] Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Atherosclerosis2019;290:140-205

[2] de Isla L,Muñiz-Grijalvo O.SAFEHEART InvestigatorsA resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort.Eur J Prev Cardiol2022;29:795-801

[3] McKay AJ,Ray KK.Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort.Atherosclerosis2022;358:68-74

[4] Galema-Boers AM,Engelkes SR,Roeters van Lennep JE.Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy.J Clin Lipidol2018;12:409-16

[5] Akioyamen LE,Chu A,Ko DT.Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.J Clin Lipidol2019;13:15-30

[6] Romero-Jiménez MJ,Gutiérrez-Cortizo EN.Predictors of cardiovascular risk in familial hypercholesterolemia.Curr Opin Lipidol2023;34:272-7

[7] Tada H,Nohara A,Mabuchi H.Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia.Eur Heart J2017;38:1573-9

[8] Isla LP,Watts GF.SAFEHEART InvestigatorsLong-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study.Lancet Diabetes Endocrinol2024;12:643-52

[9] Shin DG,Kim DI.Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - a study supported by the Korean Society of Lipidology and Atherosclerosis.Atherosclerosis2015;243:53-8

[10] Chan DC,Hooper AJ.Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.Int J Cardiol2015;201:633-8

[11] Bianconi V,Pirro M.International Lipid Expert Panel (ILEP)Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.Trends Cardiovasc Med2021;31:205-15

[12] Elshorbagy A,Barkas F.Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry.Eur Heart J2025;46:1127-40 PMCID:PMC11931214

[13] Harada-Shiba M,Ohmura H.Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022.J Atheroscler Thromb2023;30:558-86

[14] Lee CJ,Kang HJ.Task Force Team for Familial HypercholesterolemiaKorean Society of Lipid and Atherosclerosis2022 consensus statement on the management of familial hypercholesterolemia in Korea.J Lipid Atheroscler2022;11:213-28 PMCID:PMC9515735

[15] Tada H,Takeji Y,Kawashiri MA.Impact of changes in Achilles tendon thickening on cardiovascular events in patients with familial hypercholesterolemia.Am J Prev Cardiol2024;18:100660 PMCID:PMC10999807

[16] Santos RD,Hegele RA.International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelDefining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.Lancet Diabetes Endocrinol2016;4:850-61

[17] Shishikura D,Michikura M.Clinical impact of lipoprotein (a) and cumulative low-density lipoprotein cholesterol exposure on coronary artery disease in patients with heterozygous familial hypercholesterolemia.J Atheroscler Thromb2025;32:100-10 PMCID:PMC11706985

[18] Tada H,Nohara A,Takamura M.Effect of cumulative exposure to low-density lipoprotein-cholesterol on cardiovascular events in patients with familial hypercholesterolemia.Circ J2021;85:2073-8

[19] Tromp TR,Nurmohamed NS.Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.Atherosclerosis2023;365:27-33

[20] Pérez de Isla L,Mata N.Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study).Circulation2017;135:2133-44

[21] Paquette M,Baass A.The montreal-FH-SCORE: a new score to predict cardiovascular events in familial hypercholesterolemia.J Clin Lipidol2017;11:80-6

[22] Paquette M,Cariou B.Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia.Arterioscler Thromb Vasc Biol2021;41:2632-40

[23] Guerin M.Reverse cholesterol transport in familial hypercholesterolemia.Curr Opin Lipidol2012;23:377-85

[24] Tada H,Nohara A.Impact of high-density lipoprotein function, rather than high-density lipoprotein cholesterol level, on cardiovascular disease among patients with familial hypercholesterolemia.Circ J2023;87:806-12

[25] Ogura M,Harada-Shiba M.Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.Arterioscler Thromb Vasc Biol2016;36:181-8

[26] Versmissen J,Yahya R.Familial hypercholesterolaemia: cholesterol efflux and coronary disease.Eur J Clin Invest2016;46:643-50 PMCID:PMC5113689

[27] Clarke SL.Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?.Curr Opin Lipidol2023;34:52-8 PMCID:PMC9994798

[28] Ibrahim S,Reeskamp LF.LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia.Atherosclerosis2024;397:117610

[29] Paquette M,Thériault S,Paré G.Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia.J Clin Lipidol2017;11:725-732.e5

[30] Gallo A,Charrière S.REFERCHOL and SAFEHEART InvestigatorsThe added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia.JACC Cardiovasc Imaging2021;14:2414-24

[31] Miname MH,Moraes SR.Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy.JACC Cardiovasc Imaging2019;12:1797-804

[32] Tada H,Usui S.Coronary artery and carotid artery plaques in patients with heterozygous familial hypercholesterolemia.JACC Adv2023;2:100594 PMCID:PMC11198480

[33] Bea AM,Jarauta E.Association between the presence of carotid artery plaque and cardiovascular events in patients with genetic hypercholesterolemia.Rev Esp Cardiol2017;70:551-8

[34] Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).Lancet2021;398:1713-25